The company, through Dabur Pharma Ltd. does toxicology tests and markets ayurvedic medicines in a scientific manner. They have researched new medicines which will find use in O.T. all over the country therein opening a new market.

Dabur Foods, a subsidiary of Dabur India is expecting to grow at 25%. Its brands of juices, namely, Real and Active, together make it the market leader in the Fruit Juice Category.

Dabur is the co-owner of the IPL team Kings XI Punjab.

Key Facts:

Milestones:

IT Initiatives

• Migration from Baan and Mfg ERP Systems to centralized SAP ERP system from 1st April 2006 for all business units.
• Implementation of a country wide new WAN Infrastructure for running centralized ERP system.
• Setting up of new Data Centre at KCO Head Office.
• Extension of Reach System to distributors for capturing Secondary Sales Data.
• Roll out of IT services to new plants and CFAs.

• Upcoming Challenges
  • Forward Integration of SAP with Distributors and Stockists.
  • Backward Integration of SAP with Suppliers.
  • Implementation of new POS system at Stockist point and integration with SAP-ERP.
  • Implementation of SAP HR and payroll.
  • SAP Roll-out to DNPL and other new businesses.

Registered Office:

Corporate Office:

List of offices

http://www.dabur.com

By 2007, Cipla became the world’s largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed (multinational brand-name drugs are much more expensive, so in money terms Cipla medicines are probably somewhere down the list). Roughly 40% of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs. The company is ranked third in Generic market share statistics in South African Private Sector.

Because Indian law from 1972 has allowed no (end-product) patents on drugs, and provided for compulsory licensing, Cipla was able to manufacture medicines which enjoy patent monopoly in certain other countries (particularly those where large, multinational pharmaceutical companies are based). By doing so, as well as by making an executive decision not to make profits on AIDS medication, Cipla reduced the cost of providing antiretrovirals to AIDS patients from $12,000 and beyond (monopoly prices charged by international pharma conglomerates) down to around $300 per year. Today they are able to do so for under $150 per patient per year. While this sum remains out of reach for many millions of people in Third World countries, government and charitable sources often are in a position to make up the difference for destitute patients.

The customary treatment of AIDS consists of a cocktail of three drugs. Cipla produces an all-in-one pill called Triomune which contains all three substances (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents are held by different companies. One more popular fixed dose combination is there, with the name Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine.

Exports for the year 2008 amounted to more than Rs. 21,000 million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla also offers technology for products and processes. Technical know-how/fees received during the year 2007-08 amounted to about Rs. 1500 million.

Cipla’s manufacturing facilities have been approved by the following regulatory authorities:

• Food and Drug Administration (FDA), USA
• Medicines and Healthcare products Regulatory Agency (MHRA), UK
• Therapeutic Goods Administration (TGA), Australia
• Medicines Control Council (MCC), South Africa
• National Institute of Pharmacy (NIP), Hungary
• Pharamaceutical Inspection Convention (PIC), Germany
• World Health Organisation (WHO) Department of Health, Canada
• State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil

Corporate office:

Cipla Ltd.
Mumbai Central
Mumbai – 400 008
India

Tel: +91-22-23082891, 23095521
Fax: +91-22-23070013, 23070393

http://www.cipla.com

Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. Interestingly the name Ranbaxy is a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh’s son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. His sons Malvinder Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daichi in June 2008.

Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. (Source : ORG-IMS, March, 2007). The Company has clocked sales of USD 286 Mn (2006) registering a growth of over 17%. Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the Acute segment.
In the NDDS segment, Ranbaxy is the market leader with 7.9% market share and its NDDS product portfolio contributes to about 9% of its total turnover. Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management ( Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems (Chronic)segments.

Company’s India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins, Dermatology and Pain Management Operations are structured into 9 Strategic Business Units. A publicly listed company, Ranbaxy India is also a member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largest R&D budget with an R&D spend of over US $ 100Mn. Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70′s. To support its global ambition, a first of its kind world class R&D centre was commissioned in 1994. Today, the Company’s multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Company’s robust R&D environment for both drug discovery & development reflects the Company’s commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10 programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has two programs in Phase I and the remaining in the pre-clinical stage. This includes a collaborative research program with GSK.

The company’s NDDS focus is mainly on the development of NDA/ANDAs of oral controlled- release products for the regulated markets. The Company’s first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.

Corporate Office:

Ranbaxy Laboratories Limited
Corporate Office
Plot 90, Sector 32,
Gurgaon – 122001
Haryana.
India

Tel: +91-124-4135000
Fax: +91-124-4135001

List of offices

http://www.ranbaxy.com

Established in 1983, Sun Pharma was a start-up company with five products. Since 1996, Sun has grown largely through a combination of internal growth, and acquisition of other pharmaceutical companies. Important mergers includes those of the US, Detroit based Caraco Pharm Labs, ICN Hungary (now called Alkaloida Chemical Company Exclusive Group), and that of the internationally approved plants at Halol, India as well as Bryan, Ohio, US and Cranbury, NJ, US.

A planned acquisition of Israeli Taro Pharmaceuticals initiated in March 2007 was terminated by the Taro board in May 2008.
As of 2008, it has grown to become an international speciality pharma company with more than 7000 employees, 17 manufacturing locations worldwide, two research centers, and a presence in 30 countries. It is one of the leading Indian-based pharma companies in India.

Corporate Office:

Sun Pharma
Acme Plaza,
Andheri – Kurla Rd,
Andheri (E),
Mumbai – 400 059.
India

List of offices

http://www.sunpharma.com

Dr. Reddy’s began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets – that had the advantage of not having to spend time and money on a manufacturing plant that that would gain approval from a drug licensing body such as the US’s Food and Drug Administration. Much of Reddy’s early success came in those unregulated markets, where process patents – not product patents – are recognized. With that money in the bank, the company could reverse-engineer patented drugs from more developed countries and sell them royalty-free in India and Russia. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.

The company has a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biological products, which are marketed to over 100 countries including US, Europe, Russia, Asia Pacific, India and China.

The Company conducts NCE drug discovery research in the areas of metabolic disorders, cardiovascular indications and infectious diseases. Its drug discovery effort is carried out at its research facilities in Atlanta, USA, and in Hyderabad, India.

By 2007, Dr. Reddy’s had six FDA-plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.

The company top 10 brands in the India market are:

Omez
Nise
Stamlo
Stamlo Beta
Enam
Atocor
Razo
Reclimet
Clamp
Mintop

Corporate Office:

Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No 3,
Banjara Hills,
Hyderabad – 500034,
India

Tel: +91-40-49002900
Fax: +91-40-49002999

List of office

http://www.drreddys.com